RCE Charts, page-19

Morning gentlemen,

I also have wondered weather the algorithm was potentially someone who was involved with the CR, seeing that this all started soon after we had it. I wonder if the CR was offered to the market if we would be in this same space at the moment.

I’m currently sitting in the red with this share (averaged up substantially) however the trading parcel and volumes still lead me to believe that we are getting played by a larger stake holder.

Technically and fundamentally I believe we will be back to >1.30 before the year is out. all I can say is that if I had more money spare, I would be sinking it into RCE.

· HRECApproval to Start Phase I/II Burns Wound Study. Our toxicology profile to date on 327 are better than some commercial market drugs. We know that that this stuff works on rats, mice and dogs. Once we get a human result with an announcement saying “positive data from 327…” you can name your price on the value of RECCE. This clinical testing on tropical application of R327 is by itself a company maker and perhaps the testing I am most confident about success. We also only really require 2 weeks of testing and perhaps 2 weeks of data finalisation to see if it will be a deal maker. I feel like the FIDELITY have seen this and jumped on the chance to be involved with RECCE.

· RECCE® Compounds Selected by CSIRO/DohertyInstitute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral ScreeningProgram (R327) According to the Program Selection Guidelines, Priority 1 status is defined as “highest or strong likelihood of antiviral or antiseptic efficacy – Compounds in this grouping will be eligible for stage 1 laboratory screening trials”. No set timeframe for result however November sometime.

· CMAX Clinical Trial Facility For Phase IStudy of Synthetic Antibiotic RECCE® 327. The Phase I clinical trial is a randomised, double blind, placebo-controlled single ascending dose study of 48 healthy adult subjects. The study seeks to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of RECCE® 327 following intravenous administration. Completion Q4 2020. THIS WILL BE HUGE. If we get the data back saying that R327 can be used on human trials for Phase II, you can kiss 1.50 goodbye.

Nervous times watching this share price fall, but the fall has come with no negative announcements and we have strong reason to believe that the algorithm has played a strong part in this. Buy when people are selling and sell when people are buying. Intuitive trading is something that goes against every neuron[B1] in the brain but one that more often than not pays off.

Good luck to all. I firmly believe in the science, data and fundamentals of RECCE. Its taken a long time to get to this point but from re reading old announcements this company could be valued in the billions in the coming years if all goes well.

[B1]